Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Br J Haematol. 2012 Nov;159(3):288-98. doi: 10.1111/bjh.12055. Epub 2012 Sep 21.
Nodular lymphocyte predominant Hodgkin lymphoma (nLPHL) is a unique variant of Hodgkin lymphoma with an overall good prognosis. It is conspicuously different from classical Hodgkin lymphoma (cHL) and is now recognized as distinctive form of B cell lymphoma. Although it has an indolent clinical course, it has a propensity for multiple and often late relapses. Although the majority of children present with early stage disease and without B symptoms, treatment strategy has, until recently, been identical to that used for cHL. This approach is excessively toxic as it predisposes these children and adolescents to serious late effects including end organ damage to heart, gonads, lungs, thyroid and second malignant neoplasms. The aim of this article is to review the published literature on the treatment outcomes of nLPHL in affected children and adolescents, and discuss the options for treatment including surgery, chemotherapy, radiotherapy and targeted anti-CD 20 antibody therapy.
结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）是一种独特的霍奇金淋巴瘤变异型，总体预后良好。它与经典型霍奇金淋巴瘤（cHL）明显不同，现在被认为是一种独特的 B 细胞淋巴瘤。尽管它具有惰性的临床病程，但它有多次且常常是晚期复发的倾向。尽管大多数儿童表现为早期疾病且无 B 症状，但直到最近，治疗策略与用于 cHL 的策略相同。这种方法过于有毒，因为它使这些儿童和青少年易患严重的晚期影响，包括心脏、性腺、肺、甲状腺和第二恶性肿瘤的终末器官损伤。本文的目的是回顾已发表的关于受影响儿童和青少年 NLPHL 治疗结果的文献，并讨论包括手术、化疗、放疗和靶向抗 CD20 抗体治疗在内的治疗选择。
